<DOC>
	<DOCNO>NCT01739218</DOCNO>
	<brief_summary>This randomize , open-label study evaluate efficacy safety neoadjuvant Avastin ( bevacizumab ) participant initially unresectable , FIGO stage IIIC/IV ovarian , tubal , peritoneal cancer . Participants randomize receive 8 cycle carboplatin plus paclitaxel without Avastin 15 milligram per kilogram ( mg/kg ) intravenously every 3 week Cycles 1 3 surgery . All participant receive Avastin 15 mg/kg intravenously every 3 week Cycles 6 26 . Anticipated time study treatment disease progression unacceptable toxicity occur , maximum 26 cycle .</brief_summary>
	<brief_title>A Study Avastin ( Bevacizumab ) Neoadjuvant Therapy Participants With International Federation Gynecology Obstetrics ( FIGO ) Stage IIIC/IV Ovarian , Tubal , Peritoneal Cancer , Initially Unresectable</brief_title>
	<detailed_description />
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<mesh_term>Bevacizumab</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<criteria>Adult female great equal ( &gt; /= ) 18 year age Histologically confirm document highrisk FIGO stage IIIC/IV epithelial ovarian carcinoma , fallopian tube carcinoma , primary peritoneal carcinoma Not eligible primary complete debulking surgery laparoscopic procedure judge surgeon experienced management ovarian cancer Eastern Cooperative Oncology Group ( ECOG ) performance status 0 , 1 , 2 Life expectancy &gt; /=3 month Eligible carboplatin paclitaxel chemotherapy accordance local standard Beneficiaries healthcare coverage social security system Nonepithelial ovarian cancer , ovarian tumor low malignant potential , mucinous clear cell ovarian cancer , carcinosarcoma Evidence abdominal free air explain paracentesis recent surgical procedure Previous systemic therapy ovarian cancer Previous exposure mouse CA125 antibody Current recent ( within 28 day prior Day 1 Cycle 1 ) treatment another investigational drug previous participation study Current recent ( within 10 day prior first study drug dose ) chronic daily treatment aspirin great ( &gt; ) 325 milligram ( mg ) per day Planned intraperitoneal cytotoxic chemotherapy Inadequate bone marrow , liver , renal function History myocardial infarction , unstable angina , stroke , transient ischemic attack within 6 month prior Day 1 Cycle 1 Uncontrolled hypertension Clinically significant ( active ) cardiovascular disease New York Heart Association ( NYHA ) Class II great congestive heart failure , aortic aneurism Preexisting peripheral neuropathy Common Toxicity Criteria ( CTC ) Grade &gt; /=2 Known hypersensitivity bevacizumab excipients , Chinese hamster ovary cell product recombinant humanized antibody , plan chemotherapy Pregnant lactating female History clinically active malignancy within 5 year enrollment , except tumor negligible risk metastasis death , adequately control basalcell squamouscell carcinoma skin carcinoma situ cervix breast</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>